Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro
- PMID: 7665926
- DOI: 10.1111/1523-1747.ep12321173
Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro
Abstract
Human papillomavirus type 11 (HPV-11), produced from the athymic mouse xenograft system, was shown to infect cultured neonatal human foreskin keratinocytes and the HaCaT keratinocyte cell line in vitro. Infection was documented by the appearance of HPV-11-specific spliced mRNA, detected by reverse transcriptase-polymerase chain reaction. Purified HPV-11 virions at concentrations of approximately 10(7) particles/ml could successfully evoke infection in this system. Infection was completely abrogated by preincubation of the HPV-11 inoculum with mouse anti-HPV-11 monoclonal antibodies, experimentally immunized animal sera, or sera of human patients with HPV infection. Concurrent detection of cellular mRNA for the beta-actin gene, also by reverse transcriptase-polymerase chain reaction, provided an internal control confirming RNA recovery and successful reverse transcriptase-polymerase chain reaction. Using this approach, it was possible to determine semiquantitative titers for test solutions of HPV-11-neutralizing antibodies. The in vitro system for HPV-11 infectivity and neutralization may be useful in the study of the immune response to HPV-11 infection or immunization in patients.
Similar articles
-
Detection of serologic neutralizing antibodies against HPV-11 in patients with condyloma acuminata and cervical dysplasia using an in vitro assay.Gynecol Oncol. 1997 Aug;66(2):295-9. doi: 10.1006/gyno.1997.4743. Gynecol Oncol. 1997. PMID: 9264579
-
Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs.J Infect Dis. 1992 Feb;165(2):376-80. doi: 10.1093/infdis/165.2.376. J Infect Dis. 1992. PMID: 1309849
-
Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.J Virol. 1990 Nov;64(11):5678-81. doi: 10.1128/JVI.64.11.5678-5681.1990. J Virol. 1990. PMID: 2170694 Free PMC article.
-
Papillomavirus transcripts and posttranscriptional regulation.Virology. 2013 Oct;445(1-2):187-96. doi: 10.1016/j.virol.2013.04.034. Epub 2013 May 23. Virology. 2013. PMID: 23706315 Review.
-
Papillomavirus-like particles and HPV vaccine development.Semin Cancer Biol. 1996 Dec;7(6):373-82. doi: 10.1006/scbi.1996.0046. Semin Cancer Biol. 1996. PMID: 9284529 Review.
Cited by
-
Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.J Virol. 2005 Jun;79(11):6838-47. doi: 10.1128/JVI.79.11.6838-6847.2005. J Virol. 2005. PMID: 15890923 Free PMC article.
-
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.J Virol. 1996 Sep;70(9):5875-83. doi: 10.1128/JVI.70.9.5875-5883.1996. J Virol. 1996. PMID: 8709207 Free PMC article.
-
A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Hum Vaccin Immunother. 2015;11(2):337-46. doi: 10.4161/21645515.2014.990851. Hum Vaccin Immunother. 2015. PMID: 25695397 Free PMC article.
-
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.J Virol. 2003 Dec;77(24):13125-35. doi: 10.1128/jvi.77.24.13125-13135.2003. J Virol. 2003. PMID: 14645569 Free PMC article.
-
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.Vaccine. 2007 Mar 1;25(11):2001-10. doi: 10.1016/j.vaccine.2006.11.049. Epub 2006 Nov 29. Vaccine. 2007. PMID: 17239496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources